Cargando…
Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China
This study aimed to investigate the prevalence of multidrug-resistant tuberculosis (MDR-TB) isolates resistant to the second-line antituberculosis drugs (SLDs) and its association with resistant-related gene mutations in Mycobacterium tuberculosis (M.tb) isolates from Southwest of China. There were...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536135/ https://www.ncbi.nlm.nih.gov/pubmed/28798931 http://dx.doi.org/10.1155/2017/4563826 |
_version_ | 1783253968531488768 |
---|---|
author | Hu, Y. Xu, L. He, Y. L. Pang, Y. Lu, N. Liu, J. Shen, J. Zhu, D. M. Feng, X. Wang, Y. W. Yang, C. |
author_facet | Hu, Y. Xu, L. He, Y. L. Pang, Y. Lu, N. Liu, J. Shen, J. Zhu, D. M. Feng, X. Wang, Y. W. Yang, C. |
author_sort | Hu, Y. |
collection | PubMed |
description | This study aimed to investigate the prevalence of multidrug-resistant tuberculosis (MDR-TB) isolates resistant to the second-line antituberculosis drugs (SLDs) and its association with resistant-related gene mutations in Mycobacterium tuberculosis (M.tb) isolates from Southwest of China. There were 81 isolates resistant to at least one of the SLDs among 156 MDR-TB isolates (81/156, 51.9%). The rates of general resistance to each of the drugs were as follows: OFX (66/156, 42.3%), KAN (26/156, 16.7%), CAP (13/156, 8.3%), PTO (11/156, 7.1%), PAS (22/156, 14.1%), and AMK (20/156, 12.8%). Therefore, the most predominant pattern was resistant to OFX compared with other SLDs (P < 0.001). The results of sequencing showed that 80.2% OFX-resistant MDR-TB isolates contained gyrA mutation and 88.5% KAN-resistant isolates had rrs mutations with the most frequent mutation being A1401G. These results suggest that improper use of SLDs especially OFX is a real threat to effective MDR-TB treatment not only in China but also in the whole world. Furthermore the tuberculosis control agencies should carry out SLDs susceptibility testing and rapid screening in a broader population of TB patients immediately and the SLDs should be strictly regulated by the administration in order to maintain their efficacy to treat MDR-TB. |
format | Online Article Text |
id | pubmed-5536135 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-55361352017-08-10 Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China Hu, Y. Xu, L. He, Y. L. Pang, Y. Lu, N. Liu, J. Shen, J. Zhu, D. M. Feng, X. Wang, Y. W. Yang, C. Biomed Res Int Research Article This study aimed to investigate the prevalence of multidrug-resistant tuberculosis (MDR-TB) isolates resistant to the second-line antituberculosis drugs (SLDs) and its association with resistant-related gene mutations in Mycobacterium tuberculosis (M.tb) isolates from Southwest of China. There were 81 isolates resistant to at least one of the SLDs among 156 MDR-TB isolates (81/156, 51.9%). The rates of general resistance to each of the drugs were as follows: OFX (66/156, 42.3%), KAN (26/156, 16.7%), CAP (13/156, 8.3%), PTO (11/156, 7.1%), PAS (22/156, 14.1%), and AMK (20/156, 12.8%). Therefore, the most predominant pattern was resistant to OFX compared with other SLDs (P < 0.001). The results of sequencing showed that 80.2% OFX-resistant MDR-TB isolates contained gyrA mutation and 88.5% KAN-resistant isolates had rrs mutations with the most frequent mutation being A1401G. These results suggest that improper use of SLDs especially OFX is a real threat to effective MDR-TB treatment not only in China but also in the whole world. Furthermore the tuberculosis control agencies should carry out SLDs susceptibility testing and rapid screening in a broader population of TB patients immediately and the SLDs should be strictly regulated by the administration in order to maintain their efficacy to treat MDR-TB. Hindawi 2017 2017-07-17 /pmc/articles/PMC5536135/ /pubmed/28798931 http://dx.doi.org/10.1155/2017/4563826 Text en Copyright © 2017 Y. Hu et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Hu, Y. Xu, L. He, Y. L. Pang, Y. Lu, N. Liu, J. Shen, J. Zhu, D. M. Feng, X. Wang, Y. W. Yang, C. Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China |
title | Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China |
title_full | Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China |
title_fullStr | Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China |
title_full_unstemmed | Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China |
title_short | Prevalence and Molecular Characterization of Second-Line Drugs Resistance among Multidrug-Resistant Mycobacterium tuberculosis Isolates in Southwest of China |
title_sort | prevalence and molecular characterization of second-line drugs resistance among multidrug-resistant mycobacterium tuberculosis isolates in southwest of china |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536135/ https://www.ncbi.nlm.nih.gov/pubmed/28798931 http://dx.doi.org/10.1155/2017/4563826 |
work_keys_str_mv | AT huy prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT xul prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT heyl prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT pangy prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT lun prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT liuj prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT shenj prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT zhudm prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT fengx prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT wangyw prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina AT yangc prevalenceandmolecularcharacterizationofsecondlinedrugsresistanceamongmultidrugresistantmycobacteriumtuberculosisisolatesinsouthwestofchina |